All In Biotech

Drug Trial Radar · NCT03160885

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy

Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 794 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

794

Actual

Start

Jun 12, 2017

Primary completion

Sep 4, 2018

Study completion Aug 14, 2019

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
May 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo. Maintenance objective: To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.

Conditions

  • Atopic Dermatitis

Interventions

  • TralokinumabDrug

    Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

  • PlaceboDrug

    Placebo contains the same excipients, in the same concentration only lacking tralokinumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16.Time frame: At Week 16
  2. Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI].Time frame: At Week 16

Locations

115 sites in 9 countries. Site status is shown where the registry gives one.

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • California dermatology

    Encinitas, California

  • Advanced SkinCare Surgery & Med Center

    Fullerton, California

  • USC Department of Dermatology

    Los Angeles, California

  • Thiele Dermatology Specialists, Inc

    Murrieta, California

  • Island Dermatology

    Newport Beach, California

  • Therapeutics Clinical Research

    San Diego, California

  • San Luis Dermatology and Laser Clinic

    San Luis Obispo, California

  • Southern California Dermatology, Inc.

    Santa Ana, California

  • Olympian Clinical Research

    Clearwater, Florida

  • Spotlight Research Center, LLC

    Miami, Florida

  • Private Practice - Dr. Tory P. Sullivan

    North Miami Beach, Florida

  • Marietta Dermatology Clinical Research, Inc.

    Marietta, Georgia

  • MedaPhase, Inc.

    Newnan, Georgia

  • Northwestern University

    Chicago, Illinois

  • RUSH University

    Chicago, Illinois

  • Dawes-Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Kansas City Dermatology, PA

    Overland Park, Kansas

  • Beacon Clinical Research

    Quincy, Massachusetts

  • HFMC New Center One

    Detroit, Michigan

  • The Grekin Skin Institute

    Warren, Michigan

  • Respiratory Medicine Research Institute of Michigan, PLC

    Ypsilanti, Michigan

  • Clinical Studies Group

    Henderson, Nevada

  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

  • Corning Center for Clinical Research

    Corning, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Sadick Dermatology

    New York, New York

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • University of Cincinnati Health Physicians Office

    Cincinnati, Ohio

  • Wright State Physicians

    Fairborn, Ohio

  • Aventiv Research Inc.

    Westerville, Ohio

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Paddington Testing Company, Inc.

    Philadelphia, Pennsylvania

  • Yardley Dermatology Associates

    Yardley, Pennsylvania

  • Clinical Research Center of the Carolinas

    Charleston, South Carolina

  • Rivergate Dermatology Clinical Research Center

    Goodlettsville, Tennessee

  • Bellaire Dermatology Associates

    Bellaire, Texas

  • Modern Research Associates, PLLC

    Dallas, Texas

  • Austin Institute for Clinical Research, Inc.

    Pflugerville, Texas

  • Progressive Clinical Research

    San Antonio, Texas

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.